UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $1.31 Million Stock Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) by 20.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,103 shares of the medical instruments supplier’s stock after buying an additional 1,708 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.19% of Mesa Laboratories worth $1,312,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Meros Investment Management LP bought a new position in shares of Mesa Laboratories in the 2nd quarter valued at $2,456,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Mesa Laboratories by 38.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 62,609 shares of the medical instruments supplier’s stock valued at $8,130,000 after purchasing an additional 17,450 shares in the last quarter. Eagle Asset Management Inc. boosted its stake in shares of Mesa Laboratories by 10.9% during the third quarter. Eagle Asset Management Inc. now owns 165,955 shares of the medical instruments supplier’s stock valued at $19,722,000 after purchasing an additional 16,293 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Mesa Laboratories by 7.1% during the second quarter. Dimensional Fund Advisors LP now owns 131,891 shares of the medical instruments supplier’s stock valued at $11,444,000 after purchasing an additional 8,722 shares in the last quarter. Finally, Mackenzie Financial Corp acquired a new position in shares of Mesa Laboratories in the second quarter valued at approximately $596,000. Institutional investors own 90.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on MLAB shares. Evercore ISI raised their price objective on shares of Mesa Laboratories from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Wells Fargo & Company initiated coverage on shares of Mesa Laboratories in a research note on Tuesday, August 27th. They issued an “underweight” rating and a $120.00 price objective on the stock. Finally, StockNews.com lowered Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, November 13th.

Mesa Laboratories Stock Performance

Shares of MLAB stock opened at $132.33 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.70 and a quick ratio of 0.51. Mesa Laboratories, Inc. has a one year low of $83.68 and a one year high of $141.17. The business’s 50 day simple moving average is $119.92 and its 200 day simple moving average is $115.35. The stock has a market capitalization of $718.68 million, a PE ratio of -2.90 and a beta of 0.86.

Mesa Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Friday, November 29th were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.48%. The ex-dividend date was Friday, November 29th. Mesa Laboratories’s dividend payout ratio (DPR) is presently -1.40%.

Insider Buying and Selling

In other Mesa Laboratories news, CEO Gary M. Owens sold 2,518 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $113.62, for a total value of $286,095.16. Following the transaction, the chief executive officer now directly owns 45,888 shares of the company’s stock, valued at approximately $5,213,794.56. The trade was a 5.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.40% of the stock is owned by insiders.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.